Portage Biotech Cash Flow From Operations vs. EBITDA
| PRTG Stock | USD 4.87 0.15 3.18% |
For Portage Biotech profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Portage Biotech to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Portage Biotech utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Portage Biotech's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Portage Biotech over time as well as its relative position and ranking within its peers.
Portage |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Portage Biotech. If investors know Portage will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Portage Biotech listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share 24.4 | Return On Assets (0.19) | Return On Equity (1.91) |
The market value of Portage Biotech is measured differently than its book value, which is the value of Portage that is recorded on the company's balance sheet. Investors also form their own opinion of Portage Biotech's value that differs from its market value or its book value, called intrinsic value, which is Portage Biotech's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Portage Biotech's market value can be influenced by many factors that don't directly affect Portage Biotech's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Portage Biotech's value and its price as these two are different measures arrived at by different means. Investors typically determine if Portage Biotech is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Portage Biotech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Portage Biotech EBITDA vs. Cash Flow From Operations Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Portage Biotech's current stock value. Our valuation model uses many indicators to compare Portage Biotech value to that of its competitors to determine the firm's financial worth. Portage Biotech is regarded fifth in cash flow from operations category among its peers. It also is regarded fifth in ebitda category among its peers . At this time, Portage Biotech's EBITDA is most likely to decrease significantly in the upcoming years. Comparative valuation analysis is a catch-all technique that is used if you cannot value Portage Biotech by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.Portage EBITDA vs. Cash Flow From Operations
Operating Cash Flow reveals the quality of a company's reported earnings and is calculated by deducting company's income taxes from earnings before interest, taxes, and depreciation (EBITDA). In other words, Operating Cash Flow refers to the amount of cash a firm generates from the sales or products or from rendering services. Operating Cash Flow typically excludes costs associated with long-term investments or investment in marketable securities and is usually used by investors or analysts to check on the quality of a company's earnings.
Portage Biotech |
| = | (14.3 M) |
Operating Cash Flow shows the difference between reported income and actual cash flows of the company. If a firm does not have enough cash or cash equivalents to cover its current liabilities, then both investors and management should be concerned about the company having enough liquid resources to meet current and long term debt obligations.
EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
Portage Biotech |
| = | (18.2 M) |
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
Portage EBITDA Comparison
Portage Biotech is currently under evaluation in ebitda category among its peers.
Portage Biotech Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Portage Biotech, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Portage Biotech will eventually generate negative long term returns. The profitability progress is the general direction of Portage Biotech's change in net profit over the period of time. It can combine multiple indicators of Portage Biotech, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | Projected for Next Year | ||
| Accumulated Other Comprehensive Income | 23.8 M | 25 M | |
| Operating Income | -18.3 M | -17.3 M | |
| Net Loss | -75.3 M | -71.6 M | |
| Income Tax Expense | -10.5 M | -11.1 M | |
| Income Before Tax | -85.7 M | -81.4 M | |
| Total Other Income Expense Net | -67.4 M | -64.1 M | |
| Net Interest Income | 242 K | 254.1 K | |
| Net Loss | -75.4 M | -71.6 M | |
| Net Loss | -15.2 M | -14.4 M | |
| Interest Income | 274 K | 287.7 K | |
| Change To Netincome | 106.4 M | 111.8 M | |
| Net Loss | (3.70) | (3.89) | |
| Income Quality | 0.19 | 0.18 | |
| Net Income Per E B T | 0.88 | 0.92 |
Portage Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Portage Biotech. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Portage Biotech position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Portage Biotech's important profitability drivers and their relationship over time.
Use Portage Biotech in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Portage Biotech position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Portage Biotech will appreciate offsetting losses from the drop in the long position's value.Portage Biotech Pair Trading
Portage Biotech Pair Trading Analysis
The ability to find closely correlated positions to Portage Biotech could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Portage Biotech when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Portage Biotech - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Portage Biotech to buy it.
The correlation of Portage Biotech is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Portage Biotech moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Portage Biotech moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Portage Biotech can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Portage Biotech position
In addition to having Portage Biotech in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Broad Commodities ETFs Thematic Idea Now
Broad Commodities ETFs
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Broad Commodities ETFs theme has 26 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Broad Commodities ETFs Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Your Equity Center. For more detail on how to invest in Portage Stock please use our How to Invest in Portage Biotech guide.You can also try the Correlation Analysis module to reduce portfolio risk simply by holding instruments which are not perfectly correlated.
To fully project Portage Biotech's future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Portage Biotech at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Portage Biotech's income statement, its balance sheet, and the statement of cash flows.